Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 5/20 | 0.49 |
| ▸ | CA1 | P00915 | 5/20 | 0.49 |
| ▸ | CA2 | P00918 | 5/20 | 0.49 |
| ▸ | CA7 | P43166 | 5/20 | 0.49 |
| ▸ | CA9 | Q16790 | 5/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5481626 | 0.90 | CYP2C9 (0.59) | CYP2C9CYP2C19KDM4ECA12CA1 | |
| SCHEMBL845538 | 0.90 | CYP2C9 (0.51) | CYP2C9CYP2C19KDM4ECA12CA1 | |
| SCHEMBL5488554 | 0.88 | CYP2C9 (0.47) | CYP2C9CYP2C19KDM4ECA12CA1 | |
| SCHEMBL10465834 | 0.85 | CYP2C19 (0.53) | CYP2C9CYP2C19CA12CA1CA2 | |
| SCHEMBL612735 | 0.84 | KDM4E (0.51) | KDM4ECA12CA1CA2CA7 | |
| SCHEMBL26412819 | 0.84 | CYP2C9 (0.56) | CYP2C9CYP2C19CA12CA1CA2 | |
| SCHEMBL28383608 | 0.83 | CHEK2 (0.58) | CYP2C9CYP2C19KDM4ECA12CA1 | |
| SCHEMBL14466766 | 0.83 | CYP2C9 (0.51) | CYP2C9CYP2C19CA12CA1CA2 | |
| SCHEMBL11191801 | 0.83 | CYP2C9 (0.51) | CYP2C9CYP2C19CA12CA1CA2 | |
| SCHEMBL9370802 | 0.83 | KDM4E (0.50) | KDM4ECA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250281483-A1 | TRANSCRIPTION FACTOR EB ACTIVATORS AND USES THEREOF | Astellas Engineered Small Molecules US, Incorporated | 2025-09-11 | — | — | US | disclosed |
| EP-4511112-A1 | TRANSCRIPTION FACTOR EB ACTIVATORS AND USES THEREOF | Astellas Engineered Small Molecules US, Incorporated (US) | 2025-02-26 | — | — | EP | disclosed |
| WO-2023205415-A1 | TRANSCRIPTION FACTOR EB ACTIVATORS AND USES THEREOF | MITOBRIDGE INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023205415-A1 | TRANSCRIPTION FACTOR EB ACTIVATORS AND USES THEREOF | MITOBRIDGE INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| EP-3661931-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-06-10 | — | — | EP | disclosed |
| CN-111032651-A | Heterocyclic compounds | 武田药品工业株式会社 | 2020-04-17 | — | — | CN | disclosed |
| US-10435399-B2 | HDAC6 inhibitory heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-10-08 | — | — | US | disclosed |
| US-20190135799-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-09 | — | — | US | disclosed |
| WO-2019027054-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-02-07 | — | — | WO | disclosed |
| US-8134005-B2 | Preparation and use of magnesium amides | Ludwig-Maximilians-Universitat München (DE) | 2012-03-13 | — | — | US | disclosed |
| US-20100144516-A1 | PREPARATION AND USE OF MAGNESIUM AMIDES | LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN (DE) | 2010-06-10 | — | — | US | disclosed |
| US-20090176988-A1 | Preparation and Use of Magnesium Amides | LUDWIG-MAXIMILIANS-UNIVERSITAT MUENCHEN (DE) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10435399-B2 | HDAC6 inhibitory heterocyclic compound | HDAC6, HDAC1, HDAC5 | CYP2C9 4539/4885CYP2C19 4591/4885KDM4E 522/4885 |
| US-20190135799-A1 | HETEROCYCLIC COMPOUND | HDAC1, HDAC5, HDAC6 | CYP2C9 3779/4885CYP2C19 3695/4885KDM4E 216/4885 |
| US-20250281483-A1 | TRANSCRIPTION FACTOR EB ACTIVATORS AND USES THEREOF | TFEB, MITF, CREBBP | CYP2C9 4682/4885CYP2C19 4146/4885KDM4E 2002/4885 |
| US-20090176988-A1 | Preparation and Use of Magnesium Amides | MLX, GLRX3, SFXN3 | CYP2C9 2254/4885CYP2C19 3247/4885KDM4E 3049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.